ONCOLOGY

7 in 10 patients achieved complete cytogenetic response.

Median EFS not reached at time of analysis.

Adverse cytogenetics, higher WBC predicted inferior survival.

Factors including married status prognostic of favorable survival.

Venetoclax may be a better option in patients with 13q14.3 deletion.

81% achieved minimal residual disease negativity.

65% reduction in risk for progression or death.

Findings from the CLARITY trial published in the Journal of Clinical Oncology

Median duration of response not reached in patients with complete response.

1 in 4 PET2-negative patients experienced progression at 5 years.

Largest cohort of its kind in this setting.

The drug could reduce the need for pre-emptive therapy which is associated with serious side effects.

Data from the phase 3 PRIMA trial.

Allergan issues recall of BIOCELL textured implants and tissue expanders.